Advertisement

International Journal of Hematology

, Volume 82, Issue 2, pp 152–158 | Cite as

Mesenchymal Stem Cells in Stem Cell Transplant Recipients Are Damaged and Remain of Host Origin

Article

Abstract

The aim of this study was to investigate the expansion capacity and origin of bone marrow-derived mesenchymal stem cells (MSCs) in 34 patients who received a sex-mismatched stem cell transplant (SCT). Polymerase chain reaction (PCR) analysis of the amelogenin gene (AMEL) was used to detect donor-derived MSCs. Cultured MSCs were hybridized with fluorescence in situ hybridization (FISH) probes for chromosomes X and Y to distinguish cells of donor origin from those of host origin. The MSCs of 31 of the 34 patients showed confluent stroma, and the MSCs from 24 of these 31 patients were successfully passaged more than 5 times and were able to be used for PCR and FISH analyses. The colony-forming unit-fibroblast, confluence time, and passage numbers of the MSCs and the colony-forming capacity of the hematopoietic progenitor cells of the patients were significantly different from those of 30 healthy control subjects. Flow cytometry results showed that the proportion of CD14+CD45+ cells, which are regarded as monocytes/macrophages, in cultured MSCs (fifth passage) was less than 0.04%. PCR and FISH analyses revealed that the MSC-derived cells in all 24 patients were from the host. In conclusion, the expansion capacity of MSCs in patients who receive an SCT is damaged, and the MSCs originate from the host.

Key words

Mesenchymal stem cells Expansion capacity Origin Stem cell transplant 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Appelbaum FR. Marrow transplantation for hematologic malignances: a brief review of current status and future prospects.Semin Hematol. 1988;25(suppl 3):16–22.Google Scholar
  2. 2.
    Dexter TM. Regulation of hemopoietic cell growth and development: experimental and clinical studies.Leukemia. 1989;3:469–474.PubMedGoogle Scholar
  3. 3.
    O’Flaherty E, Sparrow R, Szer J. Bone marrow stromal function from patients after bone marrow transplantation.Bone Marrow Transplant. 1995;15:207–212.PubMedGoogle Scholar
  4. 4.
    Reyes M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells.Blood. 2001;98:2615–2625.CrossRefPubMedGoogle Scholar
  5. 5.
    Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro.J Cell Physiol. 1977; 91:335–344.CrossRefPubMedGoogle Scholar
  6. 6.
    Dexter TM, Spooncer E, Simmons PJ, Allen TD. Long-term marrow culture: an overview of techniques and experience.Kroc Found Ser. 1984;18:57–96.PubMedGoogle Scholar
  7. 7.
    Toksoz D, Zsebo K, Smith K, et al. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor.Proc Natl Acad Sci U S A. 1992;89:7350–7354.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses.Exp Hematol. 2000;28:875–884.CrossRefPubMedGoogle Scholar
  9. 9.
    Fried W, Kedo A, Barone J. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma.Cancer Res. 1977;37:1205–1209.PubMedGoogle Scholar
  10. 10.
    McManus PM, Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies.Blood. 1984;64:1036–1041.PubMedGoogle Scholar
  11. 11.
    Burnett AK. Autologous transplantation in acute leukemias, including purging.Curr Opin Oncol. 1990;2:263–273.CrossRefPubMedGoogle Scholar
  12. 12.
    Meloni G, De Fabritiis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.Blood. 1990;75:2282–2285.PubMedGoogle Scholar
  13. 13.
    Uhlman DL, Verfaillie C, Jones RB, Luikart SD. BUNC treatment of marrow stromal monolayers reversibly alters haematopoiesis.Br J Haematol. 1991;78:3304–3309.CrossRefGoogle Scholar
  14. 14.
    Greenberger JS. Toxic effects on the hematopoietic microenvironment.Exp Hematol. 1991;19:1101–1109.PubMedGoogle Scholar
  15. 15.
    Betticher DC, Huxol H, Muller R, Speck B, Nissen C. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.Exp Hematol. 1993;21:1517–1521.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Carlo-Stella C, Tabilio A, Regazzi E, et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.Bone Marrow Transplant. 1997;20:465–471.CrossRefGoogle Scholar
  17. 17.
    Keating A, Singer JW, Killen PD, et al. Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man.Nature. 1982;298:280–283.CrossRefGoogle Scholar
  18. 18.
    Simmons PJ, Przepioka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation.Nature. 1982;298:280–283.CrossRefGoogle Scholar
  19. 19.
    Tanaka J, Kasai M, Imamura M, et al. Evaluation of mixed chimaerism and origin of bone marrow derived fibroblastoid cells after allogeneic bone marrow transplantation.Br J Haematol. 1994; 86:436–438.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Koc ON, Peters C, Aubourg P, et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases.Exp Hematol. 1999;27:1675–1681.CrossRefPubMedGoogle Scholar
  21. 21.
    Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation.Blood. 2000;96:3637–3643.PubMedGoogle Scholar
  22. 22.
    Awaya N, Rupert K, Bryant E, Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation.Exp Hematol. 2002; 30:937–942.CrossRefPubMedGoogle Scholar
  23. 23.
    Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT.Bone Marrow Transplant. 1996;17:273–275.PubMedGoogle Scholar
  24. 24.
    Lau EC, Mohandas TK, Shapiro LJ, Slavkin HC, Snead ML. Human and mouse amelogenin gene loci are on the sex chromosomes.Genomics. 1989;4:162–168.CrossRefPubMedGoogle Scholar
  25. 25.
    Nakahori Y, Takenaka O, Nakagome Y. A human X-Y homologous region encodes “amelogenin”.Genomics. 1991;9:264–269.CrossRefPubMedGoogle Scholar
  26. 26.
    Sivagami AV, Rao AR, Varshney U. A simple and cost-effective method for preparing DNA from the hard tooth tissue, and its use in polymerase chain reaction amplification of amelogenin gene segment for sex determination in an Indian population.Forensic Sci Int. 2000;110:107–115.CrossRefPubMedGoogle Scholar
  27. 27.
    Purton LE, Mielcarek M, Torok-Storb B. Monocytes are the likely candidate ‘stromal’ cell in G-CSF-mobilized peripheral blood.Bone Marrow Transplant. 1998;21:1075–1076.CrossRefPubMedGoogle Scholar
  28. 28.
    Koc ON, Lazarus HM. Mesenchymal stem cells: heading into the clinic.Bone Marrow Transplant. 2001;27:235–239.CrossRefPubMedGoogle Scholar
  29. 29.
    Cahill RA, Jones O, Mueller TO, et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplant using bone fragments and cultured osteoblast like cells [abstract].Blood 2002;100. Abstract 228.Google Scholar
  30. 30.
    Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.Nat Med. 1999;5:309–313.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  1. 1.Peking University Institute of HematologyPeking University People’s HospitalBeijingPeople’s Republic of China

Personalised recommendations